-
3
-
-
0026801167
-
Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells
-
3. Holtzman MJ, Turk J, Shornick LP (1992) Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem 267: 21438-21445
-
(1992)
J Biol Chem
, vol.267
, pp. 21438-21445
-
-
Holtzman, M.J.1
Turk, J.2
Shornick, L.P.3
-
5
-
-
0031420668
-
Distribution of COX-1 and COX-2 in normal and inflamed tissues
-
5. Seibert WW, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P (1997) Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 400A: 167-170
-
(1997)
Adv Exp Med Biol
, vol.400 A
, pp. 167-170
-
-
Seibert, W.W.1
Zhang, Y.2
Leahy, K.3
Hauser, S.4
Masferrer, J.5
Isakson, P.6
-
6
-
-
0032572519
-
The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins
-
6. Bjorkman DJ (1998) The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 105[suppl 1B]: 8S-12S
-
(1998)
Am J Med
, vol.105
, Issue.SUPPL. 1B
-
-
Bjorkman, D.J.1
-
7
-
-
0032076219
-
Cyclooxygenase-1 and cyclooxygenase-2. Selectivity of widely used nonsteroidal anti-inflammatory drugs
-
7. Cryer B, Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2. Selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413-421
-
(1998)
Am J Med
, vol.104
, pp. 413-421
-
-
Cryer, B.1
Feldman, M.2
-
8
-
-
0030969888
-
Differentiating among nonsteroidal anti-inflammatory drugs by pharmacokinetic and pharmacodynamic profiles
-
8. Fenner H (1997) Differentiating among nonsteroidal anti-inflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Semin Arthritis Rheum 26[suppl 1]: 28-33
-
(1997)
Semin Arthritis Rheum
, vol.26
, Issue.SUPPL. 1
, pp. 28-33
-
-
Fenner, H.1
-
9
-
-
0030982146
-
Mechanism of action of aspirin-like drugs
-
9. Vane JR, Botting RM (1997) Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 26[suppl 1]: 2-10
-
(1997)
Semin Arthritis Rheum
, vol.26
, Issue.SUPPL. 1
, pp. 2-10
-
-
Vane, J.R.1
Botting, R.M.2
-
10
-
-
0031921289
-
Scientific rationale for specific inhibition of COX-2
-
10. Botten WW (1998) Scientific rationale for specific inhibition of COX-2. J Rheumatol 51: 2-7
-
(1998)
J Rheumatol
, vol.51
, pp. 2-7
-
-
Botten, W.W.1
-
11
-
-
0028044609
-
Towards a better aspirin
-
11. Vane JR (1994) Towards a better aspirin. Nature 367: 215-216
-
(1994)
Nature
, vol.367
, pp. 215-216
-
-
Vane, J.R.1
-
12
-
-
0032788729
-
Rofecoxib (VioxxTM, MK-0966, 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone): A potent, selective, and orally active cyclooxygenase-2 inhibitor - Pharmacological and biochemical profiles
-
12. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, Tagari P, Therien M, Vickers P, Visco D, Wang Z, Webb J, Wong E, Xu LJ, Young RN, Zamboni R, Riendeau D (1999) Rofecoxib (VioxxTM, MK-0966, 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone): a potent, selective, and orally active cyclooxygenase-2 inhibitor - pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551-560
-
(1999)
J Pharmacol Exp Ther
, vol.290
, pp. 551-560
-
-
Chan, C.C.1
Boyce, S.2
Brideau, C.3
Charleson, S.4
Cromlish, W.5
Ethier, D.6
Evans, J.7
Ford-Hutchinson, A.W.8
Forrest, M.J.9
Gauthier, J.Y.10
Gordon, R.11
Gresser, M.12
Guay, J.13
Kargman, S.14
Kennedy, B.15
Leblanc, Y.16
Leger, S.17
Mancini, J.18
O'Neill, G.P.19
Ouellet, M.20
Patrick, D.21
Percival, M.D.22
Perrier, H.23
Prasit, P.24
Rodger, I.25
Tagari, P.26
Therien, M.27
Vickers, P.28
Visco, D.29
Wang, Z.30
Webb, J.31
Wong, E.32
Xu, L.J.33
Young, R.N.34
Zamboni, R.35
Riendeau, D.36
more..
-
13
-
-
0018830990
-
2 production in healthy subjects
-
2 production in healthy subjects. Thromb Res 17: 317-327
-
(1980)
Thromb Res
, vol.17
, pp. 317-327
-
-
Patrono, C.1
Ciabattoni, G.2
Pinca, E.3
Pugliese, F.4
Castrucci, G.5
De Salvo, A.6
Satta, MA.7
Peskar, B.A.8
-
14
-
-
0030022032
-
A human whole blood assay for the clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
-
14. Brideau C, Kargman S, Liu S, Dallob A, Ehrich E, Rodger I, Chan C (1996) A human whole blood assay for the clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45: 68-74
-
(1996)
Inflamm Res
, vol.45
, pp. 68-74
-
-
Brideau, C.1
Kargman, S.2
Liu, S.3
Dallob, A.4
Ehrich, E.5
Rodger, I.6
Chan, C.7
-
16
-
-
0027940487
-
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
-
16. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone J, Ganci A, Créminon C, Maclouf J, Patrono C (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271: 1705-1712
-
(1994)
J Pharmacol Exp Ther
, vol.271
, pp. 1705-1712
-
-
Patrignani, P.1
Panara, M.R.2
Greco, A.3
Fusco, O.4
Natoli, C.5
Iacobelli, S.6
Cipollone, J.7
Ganci, A.8
Créminon, C.9
Maclouf, J.10
Patrono, C.11
-
17
-
-
0033064312
-
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
-
17 Ehrich E, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold J, De Schepper PJ, Mehlisch D, Gertz B (1999) Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 65: 336-347
-
(1999)
Clin Pharmacol Ther
, vol.65
, pp. 336-347
-
-
Ehrich, E.1
Dallob, A.2
De Lepeleire, I.3
Van Hecken, A.4
Riendeau, D.5
Yuan, W.6
Porras, A.7
Wittreich, J.8
Seibold, J.9
De Schepper, P.J.10
Mehlisch, D.11
Gertz, B.12
-
18
-
-
0001305554
-
MK-0966, A specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 26-week controlled clinical trial
-
18. Cannon G, Caldwell J, Holt P, Mclean B, Zeng Q, Ehrich E, Seidenberg B, Bolognese J, Daniels B (1998) MK-0966, A specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 26-week controlled clinical trial (abstract 983). Arthritis Rheum 41[suppl]: 196
-
(1998)
Arthritis Rheum
, vol.41
, Issue.SUPPL.
, pp. 196
-
-
Cannon, G.1
Caldwell, J.2
Holt, P.3
McLean, B.4
Zeng, Q.5
Ehrich, E.6
Seidenberg, B.7
Bolognese, J.8
Daniels, B.9
-
19
-
-
0001305554
-
MK-0966, A specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial
-
19. Saag K, Fisher C, McKay J, Ehrich E, Zhao PL, Seidenberg B, Bolognese J, Daniels B (1998) MK-0966, A specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial (abstract 984). Arthritis Rheum 41[suppl]: 196
-
(1998)
Arthritis Rheum
, vol.41
, Issue.SUPPL.
, pp. 196
-
-
Saag, K.1
Fisher, C.2
McKay, J.3
Ehrich, E.4
Zhao, P.L.5
Seidenberg, B.6
Bolognese, J.7
Daniels, B.8
-
20
-
-
0024427759
-
The increase in urinary excretion of 6 β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction
-
20. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Borres P, Michel H, Beaune P, Maurel P (1989) The increase in urinary excretion of 6 β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28: 373-387
-
(1989)
Br J Clin Pharmacol
, vol.28
, pp. 373-387
-
-
Ged, C.1
Rouillon, J.M.2
Pichard, L.3
Combalbert, J.4
Bressot, N.5
Borres, P.6
Michel, H.7
Beaune, P.8
Maurel, P.9
-
21
-
-
0033059318
-
Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection
-
21. Woolf E, Matuszewski B (1999) Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection. J Chromatogr B Biomed Sci Appl 730: 221-227
-
(1999)
J Chromatogr B Biomed Sci Appl
, vol.730
, pp. 221-227
-
-
Woolf, E.1
Matuszewski, B.2
-
22
-
-
0029073404
-
Renal effects of over-the counter analgesics
-
22. Whelton A (1995) Renal effects of over-the counter analgesics. J Clin Pharmacol 35: 454-463
-
(1995)
J Clin Pharmacol
, vol.35
, pp. 454-463
-
-
Whelton, A.1
-
23
-
-
0027478126
-
Renal toxicity of non-steroidal anti-inflammatory drugs
-
23. Murray MD, Brater DC (1993) Renal toxicity of non-steroidal anti-inflammatory drugs. Annu Rev Pharmacol 32: 435-465
-
(1993)
Annu Rev Pharmacol
, vol.32
, pp. 435-465
-
-
Murray, M.D.1
Brater, D.C.2
-
24
-
-
0031975062
-
Non-steroidal anti-inflammatory drug-induced renal failure: A brief review of the role of cyclo-oxygenase isoforms
-
24. Venturi CM, Isakson P, Needleman P (1998) Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclo-oxygenase isoforms. Curr Opin Nephrol Hypertens 7: 79-82
-
(1998)
Curr Opin Nephrol Hypertens
, vol.7
, pp. 79-82
-
-
Venturi, C.M.1
Isakson, P.2
Needleman, P.3
-
25
-
-
33751335393
-
Localisation of cyclo-oxygenase 1 and 2 in adult and fetal human kidney: Implication for renal function
-
25. Komhoff M, Grone HJ, Klein T, Seybert HW, Nusing RM (1997) Localisation of cyclo-oxygenase 1 and 2 in adult and fetal human kidney: implication for renal function. Am J Physiol 272: F460-F468
-
(1997)
Am J Physiol
, vol.272
-
-
Komhoff, M.1
Grone, H.J.2
Klein, T.3
Seybert, H.W.4
Nusing, R.M.5
-
26
-
-
0031679914
-
Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity
-
26. Khan K, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, Trump BF, Maziasz TJ, Alden CL (1998) Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 26: 612-620
-
(1998)
Toxicol Pathol
, vol.26
, pp. 612-620
-
-
Khan, K.1
Venturini, C.M.2
Bunch, R.T.3
Brassard, J.A.4
Koki, A.T.5
Morris, D.L.6
Trump, B.F.7
Maziasz, T.J.8
Alden, C.L.9
-
27
-
-
0031868142
-
Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations
-
27. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK (1998) Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 63: 617-622
-
(1998)
Clin Pharmacol Ther
, vol.63
, pp. 617-622
-
-
Kovacs, S.J.1
Martin, D.E.2
Everitt, D.E.3
Patterson, S.D.4
Jorkasky, D.K.5
|